Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants

NCT03636906 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03636906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03636906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Completed
Start date
April 8, 2019
Completion date
July 22, 2021
Enrollment
201 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus infections